Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mechanism of Allogeneic Umbilical Cord Blood Therapy in Cerebral Palsy
NCT03130816Phase 2Completed
- Sponsor
- Cambridge Health Alliance
- Start
- Jul 2015
- Primary completion
- May 2019
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label trial of allogeneic human umbilical cord blood in cerebral palsy (CP), sponsored by Cambridge Health Alliance. Primary endpoint: Gross Motor Function Measure at 12 months. Started Jul 2015; status: completed.
02
Drugs
allogeneic human umbilical cord blood
03
Conditions
cerebral palsy (CP)
Beyond the preview
Go deeper on NCT03130816.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03130816.